(c) 2024 PillSync.com

SMX 400 MG TMP 80 MG Oral Tablet

INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Urinary Tract Infections For the treatment of Urinary Tract Infections due to susceptible strains of the following organisms: Escherichia coli , Klebsiella species, Enterobacter species, Morganella morganii , Proteus mirabilis and Proteus vulgaris . It is recommended that initial episodes of uncomplicated Urinary Tract Infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media For the treatment of Acute Otitis Media in pediatric patients due to susceptible strains of Streptococcus Pneumoniae or Haemophilus influenzae when in the judgment of the physician sulfamethoxazole and trimethoprim offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim tablets in pediatric patients under two years of age. Sulfamethoxazole and trimethoprim tablets are not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations of Chronic Bronchitis in Adults For the treatment of acute exacerbations of Chronic Bronchitis due to susceptible strains of Streptococcus Pneumoniae or Haemophilus influenzae when a physician deems that sulfamethoxazole and trimethoprim could offer some advantage over the use of a single antimicrobial agent. Shigellosis For the treatment of enteritis caused by susceptible strains of Shigella flexneri and Shigella sonnei when antibacterial therapy is indicated. Pneumocystis jirovecii Pneumonia For the treatment of documented Pneumocystis jirovecii Pneumonia and for prophylaxis against P. jirovecii Pneumonia in individuals who are immunosuppressed and considered to be at an increased risk of developing P. jirovecii Pneumonia. Traveler’s Diarrhea in Adults For the treatment of Traveler’s Diarrhea due to susceptible strains of enterotoxigenic E. coli .

Amneal Pharmaceuticals


9 years ago ROUND WHITE IP 271 SMX 400 MG  TMP 80 MG Oral Tablet

ROUND WHITE IP 271

9 years ago ROUND WHITE IP 271 SMX 400 MG  TMP 80 MG Oral Tablet

IP 271 ROUND WHITE

HOW SUPPLIED

SULFAMETHOXAZOLE AND TRIMETHOPRIM Tablets, USP are supplied as follows:

SULFAMETHOXAZOLE AND TRIMETHOPRIM Tablets USP, DS (double strength) 800 mg/160 mg, are supplied as white, oval, bisected tablets debossed “IP” bisect “272” on one side. They are available as follows: Bottles of 10: NDC 53746-272-11 Bottles of 24: NDC 53746-272-24 Bottles of 100: NDC 53746-272-01 Bottles of 250: NDC 53746-272-02 Bottles of 500: NDC 53746-272-05

SULFAMETHOXAZOLE AND TRIMETHOPRIM Tablets USP, 400 mg/80 mg, are supplied as white, round, bisected tablets debossed “IP” over “271” on one side. They are available as follows: Bottles of 50: NDC 53746-271-50 Bottles of 100: NDC 53746-271-01 Bottles of 500: NDC 53746-271-05 Bottles of 1000: NDC 53746-271-10 Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. DISPENSE IN TIGHT, LIGHT-RESIStanT CONTAINER.


More pills like ROUND IP 271












DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site